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ABSTRACT OF THE DISSERTATION 
Regulation of IGFBP5 and Osteoblast Functions by Nuclear Factor I 
 
by 
Laura A. Pérez-Casellas 
Doctor of Philosophy, Graduate Program in Microbiology and Molecular Genetics 
Loma Linda University, March 2013 
Dr. Thomas A. Linkhart, Chairperson 
 
The Insulin-like Growth Factor (IGF) system is a major target of GC inhibition in 
bone. We found that GCs inhibit expression of IGF binding protein-5 (IGFBP5) which 
binds IGFs and stimulates osteoblast activity by IGF dependent and independent 
mechanisms. GC-induced inhibition of IGFPB5 promoter activity was mediated by a 
composite response element that has binding sites for transcription factor activator 
protein 2 (AP-2) and nuclear factor I (NFI). The work in this dissertation identifies the 
NFI gene family as an important regulator of  IGFBP-5 transcription primarily in human, 
as well as murine osteoblasts. The  mechanism of IGFBP5 gene regulation involves direct 
binding of  the NFI members to its cis element located in the IGFBP5 promoter region. 
Knockdown of NFI mRNA expression had diverse effects on IGFBP5 expression 
depending on the gene isoform member, suggesting that NFI isoforms have different 
roles regulating this gene.  NFI had important roles during the process of osteoblast 
differentiation and mineralization, in the MCT3T3-E1 cell culture model.  Knockdown of 
murine Nfix gene expression delayed the mineralization of this cell line, and also 
decreased mRNA expression levels of  early and late osteoblastogenesis makers,  in 
particular osteocalcin.  An understanding of the role of the NFI gene family and the role 
of this family in the process of osteoblastogenic maker gene regulation can provide a new 
xiii 
alternative for pharmacological target genes for the treatment of osteoporosis, a condition 
that widely affects Americans. 
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CHAPTER ONE 
INTRODUCTION 
 
Skeletal System 
The skeleton is a complex and dynamic system that was initially thought to have a 
passive role of providing support and protection to the internal organs. Through the years, 
the functions of the skeleton have been redefined and expanded so that the skeletal 
system is now considered a complex organ system composed of multiple cell types.  
Comprising a total number of 213 bones, this system provides shape and form to the body 
allowing locomotion and protection of internal organs, and also has important roles in 
mineral homeostasis and hematopoietic cell production.   
The process of cartilaginous on long bone formation, from an initial cartilaginous 
anlagen, takes place by two different pathways, endochondral and perichondral 
ossification. In long bones, perichondral (cortical) bone is developed first directly within 
the soft connective tissue (perichondrium). Later, bone begins to form at the proximal 
and distal ends within the anlagen, creating primary ossification centers, or growth plates 
(Yang, 2008) .  
 
Osteogenesis 
The osteoblastogenesis process requires a wide array of signaling proteins 
including hormones, cytokines, growth factors, and extracellular matrix proteins. 
Appropriate stimulation of signaling pathways will determine the commitment and fate of 
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the mesenchymal stem cells (MCSs) to differentiate into osteoblasts.  Among these 
molecules the most relevant to controlling MSC commitment and diferentiation are 
osterix (Osx), Runx2 (Cbfa1/AML3), bone morphogenetic proteins (BMPs), Wnts and 
insulin like growth factors (IGFs) (McCarthy, Ji, & Centrella, 2000). 
 
Osteoblast Lineage Commitment 
The bone formation process is a very complex one and requires several signaling 
mechanisms. Osteoblasts arise from MSC.  Postnatal bone marrow stroma cells have 
significant proliferative potential and when differentiated can give rise to, adipocytes, 
myoblasts, fibrous tissue forming cells, and chondrocytes (Figure 1) (Krebsbach, 
Kuznetsov, Bianco, & Robey, 1999) under specific signaling pathways. Commitment of 
MSCs towards the osteoblastic lineage is mediated by several molecules, in particular the 
bone morphogenic (BMP) 2/4/7 and Wnt proteins. This specifically happens during the 
process of condensation, which is the pivotal stage in skeletal development and takes 
place when a previously dispersed population of mesenchymal cells forms an aggregation 
of cells, thereby facilitating the selective regulation of genes specific for either 
chondrogenesis or osteogenesis (Wu, Shi, & Cao, 2007).  
The BMP and Wnt pathways induce transcription factors that mediate 
commitment of early stem cell progenitors towards the osteoblastic lineage (Lian et al., 
2006).  BMP signaling induces Indian hedgehog (Ihh) promoting osteo/chondrogenic 
differentiation of a human chondrocytic cell line both in vivo and in vitro (Wu et al., 
2007). Another important transcription factor stimulated by these pathways is 
Runx2/Cbfa1. Runx2 may be thought of as a master switch for osteogenic differentiation, 
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 (Goldring & Goldring, 2007) 
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Figure 1.  Commitment of Mesenchymal Stem Cells. A schematic of MSC commitment 
to different cell lineages. Some of the known transcription factors playing key regulatory 
roles in the mesenchymal lineages are indicated.    
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but it also interacts with many other transcription regulators that are involved in affecting 
its expression (Ducy, 2000; Lian et al., 2006).  For example, Wnt signaling also increases 
osteoblast differentiation in part through increasing Runx-2 expression and by interacting 
with Runx2 protein to stimulate transcription of genes such as OCN (Kahler & 
Westendorf, 2003; Lian et al., 2006). As part of its pro differentiation actions, Runx-2 
suppresses pre-osteoblast proliferation targeting CDK inhibitors (CKIs) p21 and p27 
(Galindo et al., 2005; Pratap et al., 2005; Thomas et al., 2004; Westendorf et al., 2002). 
Runx-2 expression is stimulated by homeodomain proteins such as Dlx3/5 and HOXA10 
and inhibited by Msx2 at early stages of differentiation. Binding sites for Msx/Dlx, 
HOxA10, Runx2, LEF1/TCF (which mediate Wnt/βcatenin signaling), ATF4 and NFI 
reside in the OCN and Runx2 proximal promoter regions (Lian et al., 2006).  The switch 
from adipogenesis to osteogenesis is also induced by stimulation of Runx-2 expression 
through BMP signaling. The transcription factor peroxisome proliferator-activated 
receptor gamma (PPARγ2), and Runx-2 have opposing effects on the OCN promoter 
activity, which supports a mechanism for directing the fate of MSCs towards 
adipogenesis or osteogenesis (Jeon et al., 2003).  
 
Osteoblast and Mineralization 
 The osteoblast and bone lining cells are in close contact with each other, 
joined by adhering junctions. Osteoblast differentiation is accelerated by interaction of 
the type I collagen matrix with α1β1, α2β1 integrins, which activate the MAPK signaling 
pathway. The α1 Integrin increases expression of osteogenesis, and the MAPK pathway 
phosphorylates Runx-2 and induces its activity (Franceschi & Xiao, 2003). The process 
6 
of osteoblast differentiation involves three main characteristic stages that are 
characterized by unique sets of osteoblastic genes at each particular stage: proliferation, 
extracellular matrix development and mineralization. Several molecules have relevant 
roles during these processes and control each one. Expression of the most frequently 
assayed osteoblast-associated genes collagen type I (COLLI), alkaline phosphatase 
(ALP), osteopontin (OPN), osteocalcin (OCN), bone sialoprotein (BSP), and PTH/PTHrP 
receptor (PTH1R) is asynchrononously upregulated, acquired, and/or lost as the 
progenitor cells differentiate and matrix matures and mineralizes. In general, ALP 
increases during extracellular matrix development and then decreases when 
mineralization is well progressed; OPN peaks twice, first during proliferation and then 
again later during mineralization, well before certain other matrix proteins, including 
BSP and OCN peak; BSP is transiently expressed very early and then expression peaks in 
differentiated osteoblasts forming mineral; OCN expression appears and peaks with 
mineralization. Mineralization results in upregulated expression of several non-
collagenous enriched proteins, thereby providing markers of the mature osteoblast (OCN, 
OPN, BSP). These calcium and phosphate binding proteins may function in regulating 
the ordered deposition of mineral, the amount of  hydroxyapatite crystals, or crystal size 
(Kobayashi & Kronenberg, 2005).  
 
IGF System and Bone 
IGFs are the most abundant growth factors produced by bone cells and stored in 
Bone (Canalis, McCarthy, & Centrella, 1989); (Mohan, Jennings, Linkhart, & Baylink, 
1988) . IGFs regulate osteoblast proliferation, differentiation and survival (T. A. 
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Linkhart, Mohan, & Baylink, 1996; Mohan & Baylink, 1996). Moreover, IGFs are 
important for bone growth, fracture healing, and maintenance of bone mass (Hayden, 
Mohan, & Baylink, 1995).  IGFs stimulate osteoblast proliferation, bone matrix protein 
synthesis, alkaline phosphatase activity and differentiation (Mohan et al., 1988);(S. 
Linkhart, Mohan, Linkhart, Kumegawa, & Baylink, 1986; Matsuyama, Lau, & Wergedal, 
1990); (McCarthy, Centrella, & Canalis, 1989). IGFs also enhance osteoclast formation 
and activity. The IGF system is composed of IGF-I/II, growth hormone, type I and type II 
IGF-receptor, six high affinity binding proteins (IGFBPs), and IGFBP proteases (Govoni, 
Baylink, & Mohan, 2005; Mohan & Baylink, 1996). IGF-I and IGF-II are important 
paracrine and autocrine regulators of bone development, growth, repair and continuous 
renewal (Mohan et al., 2003; Yakar & Rosen, 2003).  
IGF-I/II depletion adversely affects bone growth. IGF-I/II knockout mice display 
impaired bone growth (Baker, Liu, Robertson, & Efstratiadis, 1993);(J. P. Liu, Baker, 
Perkins, Robertson, & Efstratiadis, 1993) (Woods, Camacho-Hubner, Barter, Clark, & 
Savage, 1997); (DeChiara, Efstratiadis, & Robertson, 1990); (Wolf, Rapp, Blum, Kolb, & 
Brem, 1995); (Powell-Braxton, Hollingshead, Giltinan, Pitts-Meek, & Stewart, 1993). 
IGF-I knockout mice model has severe deficit on bone mineral density as well as,  
skeletal disruptions exemplified by a reduction in craniofacial size (McAlarney, Rizos, 
Rocca, Nicolay, & Efstratiadis, 2001). IGF-II null mice also demonstrate reduced birth 
weight (DeChiara et al., 1990). In these mice, only the paternal Igf2 allele is expressed in 
most tissues; therefore, the phenotype was only observed in progeny of males with an 
inactivated IGF-II gene. Post-natal growth was unaffected in IGF-II null mice unlike in 
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IGF-I null mice. This is believed to be due to the decreased importance of IGF-II in 
rodent post-natal development. 
 
IGFBP5 Function in Bone 
IGFBPs decrease or increase actions of IGFs on bone and other tissues (Baxter, 
2000; Clemmons, 1998; Ferry, Katz, Grimberg, Cohen, & Weinzimer, 1999; M. M. 
Rechler, 1993; M.M. Rechler & Clemmons, 1998).  In addition to binding extracellular 
IGF-I and IGF-II, IGFBPs affect cells by IGF-independent mechanisms that involve 
binding to  extracellular matrix or transmembrane proteins (Jones, Gockerman, Busby, 
Camacho-Hubner, & Clemmons, 1993) or by IGFBP actions within the nucleus (Amaar 
et al., 2002; Schedlich et al., 2000). 
IGFBP-5 possesses a high specific affinity for extracellular matrix proteins such 
as Type III and IV collagen, laminin and fibronectin and bone mineral (Jones et al., 
1993), and is the most abundant IGFBP stored in bone (Miyakoshi, Richman, Linkhart, 
Baylink, & Mohan, 2001).  It is expressed in osteoblasts and osteoblast precursors during 
skeletal development, and stimulates osteoblast proliferation in vitro and bone formation 
in vivo (Richman, Baylink, Lang, Dony, & Mohan, 1998; Wang, Wang, Chin, Zhou, & 
Bondy, 1995).  IGFBP-5 has complex effects on IGF actions that are cell type and 
localization specific (Mohan & Baylink, 2002; Schneider, Wolf, Hoeflich, & Lahm, 
2002). For instance, high extracellular IGFBP-5 concentrations inhibit IGF-stimulated 
vascular smooth muscle cell proliferation by sequestering free IGFs, while lower 
concentrations or extracellular matrix-bound IGFBP-5 enhance IGF activities (Xu et al., 
2004). In contrast, high extracellular IGFBP-5 concentrations increased proliferation of 
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human intestinal smooth muscle cells and prostate cancer cells by IGF dependent and 
IGF independent pathways (Kuemmerle & Zhou, 2002; Miyake, Pollak, & Gleave, 
2000).  Inhibition of IGFBP-5 expression with siRNA in U2-OS osteosarcoma cells 
increased apoptosis (Yin, Xu, & Duan, 2004), suggesting that IGFBP-5 prevents cell 
death.  Apoptosis was prevented by overexpressing IGFBP-5 in the cells, but addition of 
extracellular IGFBP-5 protein increased apoptosis (Yin et al., 2004), which  was reversed 
by addition of excess IGF-I protein. However, in other studies Addition of IGFBP-5 
increased proliferation and differentiation in osteoblast cultures through binding to 
specific cell surface sites (Andress, 1995; Andress & Birnbaum, 1992; Mohan et al., 
1995) and phosphorylation of putative IGFBP-5 receptors (Andress, 1998; Mukherjee & 
Rotwein, 2008).  On the basis of these findings, IGFBP-5 concentration and localization 
may influence effects of IGFBP5 on IGF activity.  Excess extracellular IGFBP-5 may 
inhibit IGF activity by sequestering extracellular IGFs and preventing receptor binding, 
while moderate extracellular IGFBP-5 levels may enhance IGF activity, and excess 
intracellular IGFBP-5 may enhance IGF activity or have IGF independent effects. 
In vivo studies have shown that systemic administration of IGFBP-5 to mice 
enhanced the effects of IGF-I to increase calvaria bone formation (Kling et al., 1996), 
serum osteocalcin levels (bone formation marker) and femoral bone ALP activity 
(Richman, Baylink, Lang, Dony, & Mohan, 1999).  Also, treatment of ovariectomized 
mice with a C-terminal truncated form of IGFBP-5, which binds IGFs with reduced 
affinity, augmented spinal and femural bone densities, bone formation rates and 
osteoblast numbers in the absence of IGF-I (Andress, 2001). Furthermore, local injections 
of IGFBP-5 in the outer periosteum of the parietal bone of IGF-I knockout mice 
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increased markers of bone formation to concentrations comparable to those seen in wild-
type mice (Miyakoshi et al., 2001), suggesting that these IGFBP-5 actions are IGF 
independent. 
 
Glucocorticoids 
The IGF system is one of the major targets of GC inhibition in bone (Rosen & 
Donahue, 1998; Rosen, Donahue, & Hunter, 1994). GCs inhibit IGF anabolic activity in 
bone by changing expression of IGFBPs, for example by decreasing IGFBP-5 and 
IGFBP-3 and increasing IGFBP-4 mRNA levels in human osteoblasts (Chevalley, 
Strong, Mohan, Baylink, & Linkhart, 1996).  In rodents, GCs inhibited osteoblast IGF I 
expression, but in human bone marrow osteoblast precursors, GCs did not affect IGF I or 
IGF II expression (Cheng et al., 1998). 
Therapeutic GCs are steroid hormone analogs that are frequently used to treat 
auto-immune and inflammatory diseases (Boumpas, Chrousos, Wilder, Cupps, & Balow, 
1993). These drugs can cause multiple adverse side effects, the most severe of which is 
bone loss and GC-induced osteoporosis (GIOP) (Lukert & Raisz, 1990, 1994). The 
principal deleterious effect of GCs on the skeleton is to inhibit bone formation by 
inhibiting proliferation and differentiation of osteoblast lineage cells, and increasing 
osteoblast apoptosis (Adler & Rosen, 1994; Rackoff & Rosen, 1998). These adverse 
effects are mediated mainly by glucocorticoid receptor (GR) activation or inhibition of 
transcription of specific genes, many of which encode growth factors, transcription 
factors or cell cycle regulators. Almost all inhibitory actions of GR on gene expression 
11 
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Figure 2.  Insulin-like growth factor 5 protein structure.   IGFBP5 can be divided into 3 
main protein domains. The N-terminus is the primary IGF binding site. The linker 
domain is susceptible to proteolytic cleavage. The C-terminus is involved in extracellular 
cell matrix protein interaction, and contains a putative nuclear localization signal.  
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are mediated by interactions of GR with other TFs rather than GR binding to DNA 
sequences. For this reason, discovery of TFs inhibited by GR in osteoblasts will not only 
reveal mechanisms of GC inhibition but will also identify TFs that are important in 
regulating osteoblast functions.  
 
IGFBP5 Gene Promoter   
IGFBP-5 transcription is positively regulated by prostaglandins, progesterone, 
cAMP, PTH, IGF-I and II and inhibited by GCs and BMP-7 (Boonyaratanakornkit et al., 
1999b; Gabbitas & Canalis, 1998; Gabbitas, Pash, Delany, & Canalis, 1996; Ji, Chang, 
Centrella, & McCarthy, 2003; Ji, Chen, Centrella, & McCarthy, 1999; Yeh & Lee, 2000). 
The proximal few hundred bp of rat, human and mouse IGFBP-5 gene promoters are 
highly conserved and contain several putative transcription factor binding sites, including 
a TATA box, CAAT box, cEBP responsive element, Myb/E-box, and overlapping AP-2 
and NFI sites (Allander et al., 1994; Duan & Clemmons, 1995; Ji et al., 1999; Kou, 
Mittanack, Fu, & Rotwein, 1995). Deletion of the segment containing the AP-2 and NFI 
sites reduced basal promoter activity but not PGE2 and cAMP activation, while mutation 
of the c/EBP binding site reduced PGE2 activation. Mutation of the Myb site completely 
inhibited promoter activity.  The proximal promoter region containing the closely 
associated Myb, NFI and AP-2 sites may function as a composite response element, 
although the role of the Myb site is unclear. 
Cortisol inhibited mouse IGFBP-5 transcription in rat osteoblasts, and this was 
prevented by mutation of the Myb/E-box motif (Gabbitas et al., 1996). However, our 
group found that mutation of a slightly different sequence (having one extra A) in the 
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human IGFBP-5 promoter, in the composite response element, did not prevent Dex 
inhibition. We identified a composite response element in the proximal IGFBP-5 gene 
promoter that contributes to basal promoter activation in human osteoblasts and is 
required for Dex inhibition. This element contains overlapping binding sequences for AP-
2 and NFI.  Although GR did not bind to the IGFBP-5 promoter directly, Dex induced 
GR binding to AP-2 and AP-2 overexpression prevented GC inhibition of IGFBP-5 
promoter activity. This suggests that ligand dependent GR binding to AP-2 is involved in 
GR inhibition of IGFBP-5 transcription.  Recently, we found that NFI activates BP-5 
promoter activity to a greater degree than AP-2, NFI overexpression also reverses 
inhibition by GCs, and that GR binds to NFIB.  
 
Nuclear Factor I Gene Family 
The NFI gene family is composed of four members in vertebrates, NFIA, NFIB, 
NFIC and NFIX. These proteins play wide reaching roles in viral DNA replication, 
regulation of gene transcription and development.  Gene knockout studies of the Nfi 
family in mice have shown that Nfia -/- mice display mainly neuroanatomical defects 
(Shu, Butz, Plachez, Gronostajski, & Richards, 2003), Nfib -/- mice show lung and brain 
defects (Steele-Perkins et al., 2005), Nfic knockout caused primarily a disruption of tooth 
root and underlying mandibular bone development (Steele-Perkins et al., 2003). The first 
Nfix -/- mouse knockout model reported showed severe brain malformation that was 
mainly due to impaired endochondral ossification and decreased mineralization in the 
vertebrae and long bones (Driller et al., 2007). A second Nfix knockout model showed 
altered prenatal brain development that suggested a defect in cell migration in specific 
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parts of the brain during development, as previously demonstrated by Driller et al 
(Campbell et al., 2008) .  
The NFI family members contain a highly conserved N-terminal DNA binding 
domain and a heterogeneous proline rich transactivation and repression domain. Several 
studies reported that NFI proteins bound as dimers to the dyad symmetric consensus 
sequence TTGGC (N5) GCCAA on duplex DNA (Gronostajski, Adhya, Nagata, 
Guggenheimer, & Hurwitz, 1985). Alternative splicing in all NFI genes generates 
multiple isoforms, most of which retain the conserved DNA binding and dimerization 
domains.  NFIB3 is a naturally truncated isoform derived from the human NFIB gene that 
does not contain the transactivation domain and was reported to function as a 
transcriptional repressor (Y. Liu, Bernard, & Apt, 1997). Transcriptional regulation by 
the four NFI gene members varied depending on the cell type and the specific gene 
promoter. NFIA inhibited Cbfa1/Runx2 promoter activity specifically in mouse non-
osteoblasts, and based on its absence in osteoblasts was proposed to allow osteoblast 
specific expression (Zambotti, Makhluf, Shen, & Ducy, 2002).  However, the study was 
based on comparison of a rat osteosarcoma cell line as the only osteoblast model, to 
mouse fibroblast cell lines, so relevance of these observations to regulation of osteoblast 
differentiation is unclear. Recently, a microarray analysis of MC3T3-E1 mouse 
osteoblasts, demonstrated that the GC, Dexamethasone induced expression of several 
transcription factors including NFIB (Leclerc et al., 2004). These findings are intriguing 
considering our findings that Dexamethasone inhibited NFIB activation of IGFBP-5 
transcription. Perhaps this could be a dose-dependant feedback mechanism of 
Dexamethasone treatment. 
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NFI proteins functionally interact with and/or bind other transcription factors and 
co-activators including GR, AP-2, SRC-1, AP-1, Oct-1 and CBP/p300 (Chaudhry, 
Vitullo, & Gronostajski, 1999; Ji et al., 1999; Mukhopadhyay, Wyszomierski, 
Gronostajski, & Rosen, 2001).  NFI has also been reported to affect chromatin 
remodeling on the mouse mammary tumor virus promoter (Hebbar & Archer, 2007). NFI 
and AP-2 interact in regulating expression of several genes that are relevant to 
osteoblasts, but have not previously been reported to bind each other. NFI/ AP-2 motifs 
have been identified in promoters of Type I α1 and α2 collagen genes, and may mediate 
TGF-β stimulation and TNF-α inhibition of mouse α2 (I) collagen transcription (Miao, 
Potter, Anania, Rennie-Tankersley, & Mezey, 1999; Rossi et al., 1988). In some genes 
like stellate cell type I collagen, binding of NFI and another transcription factor 
(including AP-2) to overlapping sites of  promoter sequence is mutually exclusive (Chen, 
Beno, & Davis, 1996).  
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Abstract 
Insulin-like growth factor binding protein 5 (IGFBP5) is expressed in many cell 
types including osteoblasts and modulates IGF activities. IGFBP5 may affect osteoblasts 
and bone formation, in part by mechanisms independent of binding IGFs. The highly 
conserved IGFBP5 proximal promoter within 100 nucleotides of the start of transcription 
contains functional cis regulatory elements for C/EBP, Myb and AP-2. We report 
evidence for a functional Nuclear Factor I (NFI) cis element that mediates activation or 
repression of IGFBP5 transcription by the NFI gene family. All four NFI genes were 
expressed in human osteoblast cultures and osteosarcoma cell lines. Co-transfection with 
human IGFBP5 promoter luciferase reporter and murine Nfi expression vectors showed 
that Nfib was the most active in stimulating transcription. Nfix was less active and Nfia 
and Nfic were inhibitory. Knockdown of NFIB and NFIC expression using  
siRNA decreased and increased IGFBP5 expression, respectively. Analysis of IGFBP5 
promoter deletion and mutation reporter constructs identified a functional NFI cis 
element. All four NFI proteins bound the NFI site in electrophoretic mobility shift 
experiments and NFI-B bound in Chromatin Immunoprecipitation assays. Results suggest 
that NFI proteins are important regulators of IGFBP5 expression in human osteoblasts 
and thus in modulating IGFBP5 functions in bone. 
 
Introduction 
The Insulin-like Growth Factors (IGFs) are important paracrine and autocrine 
regulators of cellular growth, differentiation and apoptosis [1-3]. IGFs are produced by 
osteoblasts and have important functions in regulating osteoblast proliferation, 
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differentiation and survival, and bone development, growth, repair and continuous 
renewal [4-6]. IGF functions are modulated by a family of binding proteins referred as 
Insulin-like growth factor binding proteins (IGFBPs). These binding proteins prolong the 
serum half-life of the IGF peptides, transport the IGFs to target cells, and modulate the 
interaction of IGFs with their surface membrane receptors [7-9]. IGFBP5 possesses a 
high specific affinity for bone matrix proteins and bone mineral [10], and is the most 
abundant IGFBP stored in bone [11]. It is expressed in osteoblasts and osteoblast 
precursors, stimulates osteoblast proliferation, and protects osteoblasts from apoptosis in 
vitro. IGFBP5 has been reported to stimulate or inhibit osteoblast differentiation and 
bone formation in vivo [3, 11-14]. While extracellular IGFBP-5 actions to inhibit IGF 
activity is mediated by binding to IGFs [3], IGFBP5 effects on bone cell growth have 
also been found to be IGF independent through binding to specific cell surface sites [15-
17] and phosphorylation of putative IGFBP receptors [18]. Moreover, recent data shows 
that IGFBP5 contains a nuclear localization sequence that mediates transport of IGFBP5 
into the nucleus [19], interacts with nuclear proteins FHL2 [20] and vitamin D receptor 
[21], and contains a functional transactivation domain localized in the N terminus [22], 
suggesting that IGFBP5 could act as a regulator of transcription. 
Previous studies reported that IGFBP5 transcription is positively regulated by 
prostaglandins, progesterone, testosterone, retinoids, cAMP, PTH, and IGFs [23-29], and 
negatively regulated by glucocorticoids and OP-1/BMP-7 [30-32]. The proximal few 
hundred bp of rat, human and mouse IGFBP5 gene promoters are highly conserved [1] 
and contains a TATA box and functional cis-acting sites for MN1, C/EBP, Myb, and AP-
2 transcription regulators [28, 33-36]. The proximal 70 bp of the promoter contains a 
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putative NFI binding site overlapping the AP-2 binding site, but the role of NFI 
transcription factors in regulation of IGFBP5 transcription has not previously been 
reported. The aim of the present study was to determine whether the putative NFI cis 
element mediates transactivation by NFI transcription factors in human osteoblasts. 
The NFI gene family is composed of four closely related members in vertebrates, NFIA, 
NFIB, NFIC and NFIX. These proteins play wide reaching roles in viral DNA replication, 
regulation of gene transcription, cell proliferation, and development. In germline gene 
knockout studies Nfia -/- mice had mainly neuroanatomical defects [37], Nfib -/- mice 
had lung and brain defects, and embryonic lethality [38], Nfic knockout inhibited 
odontoblast differentiation and caused disruption of tooth root and underlying mandibular 
bone development [39, 40], and Nfix -/- mice had brain malformation [41] and developed 
a deformation of the spine, exhibited poor growth postnatally, and had impaired 
endochondral ossification and decreased mineralization [42]]. Alternative mRNA 
splicing in all NFI genes generates multiple isoforms, most of which retain the conserved 
DNA binding and dimerization domains [43]. Transcriptional activation or repression of 
genes by NFI gene family members varies depending on cell type and gene promoter. In 
this study we found that IGFBP5 transcription is differentially modulated in human 
osteoblastic cells by members of the NFI transcription factor family through binding to 
the consensus NFI element in the proximal promoter region, suggesting that NFI proteins 
have a potential role in regulating osteoblast proliferation and differentiation. 
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Experimental Procedures 
Cell Culture 
Human osteosarcoma cell lines U2OS (hTB96), MG63, and TE85 with 
osteoblastic properties were from American Type Culture Collection (ATCC). Normal 
human osteoblasts were originally isolated as described [30] from calvaria of a 52 year 
old female (HBC 157), rib of a 32 year old male (HBR 112), and vertebrae of a 38 year 
old male (HBV 163) and 33 old male (HBV6408) obtained from Cooperative Human 
Tissue Network, which is supported by the National Cancer Institute or from non-
identified discarded surgical waste (HBV 6408) with approved exemption from the VA 
Loma Linda Health Care Network Institutional Review Board. All cells were cultured in 
DMEM (Mediatech, Inc.) plus 10% Fe5 supplemented bovine calf serum (CS, Atlanta 
Biologicals) as described previously [23]. Human choriocarcinoma cell line JEG-3 was 
obtained from ATCC and cultured in DMEM plus 10% Fetal Bovine Serum (FBS, 
Atlanta Biologicals). Cell culture plasticware was from Costar/Corning or Greiner Bio-
One. 
 
RNA Extraction and Quantitative RT-PCR 
Three independent samples of total RNA per group were isolated from 80 % 
confluent cells using a Gentra Systems Versagene™ kit (Fisher Scientific), from which 
300 ng RNA were reverse transcribed in duplicate using SuperScript III (InVitrogen) or 
iScript (BioRad). Real time PCR was performed with an Opticon 2 Fluorescent Detector 
(MJ Research/BioRad), using SYBR Green Master Mix (Qiagen) and sequence specific 
primers for human NFI-A, NFI-B, NFI-C, NFI-X, IGFBP5 and Glyceraldehyde-3-
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phosphate dehydrogenase (GAPDH) (Table 1). PCR primers (Table 1) and other 
oligodeoxynucleotides were from Integrated DNA Technologies Inc. Initially, the PCR 
products were cloned into pCR-Blunt II TOPO plasmids (InVitrogen), sequences were 
verified, and the plasmids were used to verify linearity of amplification as a function of 
template concentrations. Relative mRNA levels normalized to endogenous GAPDH 
mRNA levels are presented relative to NFI-C mRNA levels in each cell line (Table 2) or 
relative to non-targeting control in siRNA knockdown experiments (Figure 4) using the  
2-ΔΔCT Method [44]. 
 
Plasmid Constructs 
Wild type and mutant IGFBP5 promoter sequences (GenBank accession No. 
U20271) were inserted in the pGL3 basic luciferase reporter vector (Promega). In a 
previous study, a series of promoter sequences were inserted into the CAT reporter gene 
vector pJFCAT1 [23]. The sequences from bp –252 to +24 and –124 to +24 were sub-
cloned from the respective pJFCAT1 vectors into pGL3-basic, resulting in plasmids 
BP5p252-Luc and BP5p124-Luc. Promoter bp -252 corresponds to bp 1139 of GenBank 
U20271 sequence. BP5p106-Luc containing bp –106 to + 24 was made by PCR with 
BP5p252-Luc as the template using forward primer 
5’TAGCACTCGAGCATCCTTGCCTGAGTTGGG-3’ containing an XhoI site 
(underlined) and reverse primer 5’-GGCGTCTTCCATGGTGGC-3’ corresponding to the 
pGL3 vector sequence containing an NcoI site. After digestion with XhoI and NcoI, the 
fragment was sub6 cloned into pGL3-basic. BP5p70-Luc containing bp –70 to +24 was 
constructed by introducing an XhoI site at bp –70 in p252-Luc by PCR based site 
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directed mutagenesis (Quick ChangeTM, Stratagene) with primer 5’-
GTTGGGTGTTGGGAAGCTCgAgTTGCAGCTACAAACTGG-3’ and its compliment 
(altered nucleotides in lower case). The XhoI/NcoI fragment from bp –70 to +98 was 
sub-cloned from the mutant BP5p252-Luc into the pGL3-basic vector. To delete bp –70 
to –35 from BP5p252-Luc to make the BP5p252 70-35-Luc construct, a PCR product 
was made encoding bp –35 to +24 of the IGFBP5 promoter using forward primer 5’-
TAGCACTCGAGGCTATTT AAAAGCG CCTGC-3’ containing an XhoI site and 
reverse primer 5’-GGCGTCTTCCATGGTG GC-3’ containing the pGL3 NcoI site. This 
XhoI/NcoI digested PCR fragment was used to replace the XhoI/NcoI fragment in the 
mutant BP5p252-Luc that contained the added XhoI site at bp –70. 
BP5p106m1-Luc with a deletion of the overlapping NFI and AP2 binding sites (bp -54 to 
-37) was made with a synthetic DNA duplex 5’-
CCGCTCGAGGCATCCTTGCCTGAGTTG 
GGTGTTGGGAAGCTCAAATTGCAGTACAAACT [deletion]CGGCTATTTAAA 
AGCGCCTGCTCTC CCGGA GCCCCGTAGTCTCTTTGG AAACTTACTAGTCT 
GCAGGTCG-3’ containing XhoI and PstI sites (underlined sequences). The fragment 
was digested with XhoI and PstI and cloned into the BP5p106-Luc plasmid after removal 
of the wild type fragment. Mutation of the NFI site at its 5’ end to make BP5p106m2-Luc 
used a synthetic DNA duplex 5’-AGCCCGGGC TCGAGGCAT 
CCTTGCCTGAGTTGGGTGT TGGGAAG CTCAAATTGCAGCTACAAAC 
TaGtTGGCAG CCAGGGGCCGGCTAT TTAAAAGCGCC 
TGCTCTCCCGGAGCCCCG TAGTCTCTTTGGAAACTTCTGCAGGTCGACTC-3’ 
to replace the wild type sequence in BP5p106-Luc (altered nucleotides in the NFI site are 
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in lowercase, XhoI and PstI sites are underlined). BP5p106m3-Luc containing proximal 
and distal mutations in the NFI binding site of the IGFBP5 proximal promoter (bp -55 to 
-41) was made by site directed mutagenesis using primer 5’-
GCAGCTACAAACTtGCTGGCAGCaAGGG GCCGGC-3’ and its compliment (altered 
nucleotides in lower case), with BP5p106-Luc as template. DNA sequences of all 
constructs were verified by automated DNA sequencing. 
Mouse HA-tagged pCH-A (Nfia-4) [45], pCH-B(Nfib2), pCH-C (Nfic2), and pCH-X 
(Nfix2) plasmid expression vectors [46] that encode mouse NFI proteins; as well as the 
empty pCMVβ vector pCH were provided by Dr Richard M. Gronostajski (Department 
of Biochemistry, SUNY at Buffalo, Buffalo, NY, USA). A pCMV6-XL5 plasmid vector 
expressing human NFIB2 was obtained from Origene (Catalogue No. SC116683). 
 
Luciferase Reporter Assay 
TE85 and MG63 cells were transiently transfected at 50% confluency in 6 well 
plates with 0.5 μg of IGFBP5 promoter-Luc plasmid DNA and 0.125 to 1μg of each 
murine Nfi expression vector, using SuperFect (Qiagen) for TE85 cells or TurboFectin 
8.0 (OriGene Technologies) for MG63 cells. Total plasmid DNA was adjusted by 
addition of pCH. TE85 and MG63 culture medium was changed to 1mg/ml BSA in 
DMEM after 5 h or 18 h, respectively, and cells were extracted in reporter lysis buffer 
(Promega) after an additional 24 h for luciferase assay as described [23]. Luciferase 
activities were normalized to protein concentrations determined by bicinchoninic acid 
(BCA) assay (Pierce Biotechnology) and are presented as fold of control. Sample groups 
consisted of 6 replicate wells of cells. Each transient transfection experiment was 
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performed at least two times. JEG-3 cells were transiently transfected with 2μg of each 
HA-tagged pCH expression vector (Nfi) and TurboFectin 8.0 (OriGene Technologies, 
Rockville, MD). 
 
siRNA Transfection 
RNAi experiments were performed with ON-TARGET plus SMART pools (4 
targets each) targeting NFIB (L-008456-00), NFIC (L-008362-00) or NFIX (L-009250-
00) mRNAs and ON-TARGET plus siCONTROL Non Targeting siRNA #1 
(Dharmacon). MG63 cells (2 X 105 per well of 6-well plate) were transfected in Opti-
MemI (Gibco-Invitrogen) with 200 pmol of SMARTpool or siCONTROL using 
DharmaFECT-1 reagent. MG63 cells (2 X 105 per well of 6-well plate) were transfected 
in Opti-MemI(Gibco-Invitrogen) with 200 pmol of SMARTpool or siCONTROL using 
DharmaFECT-1 reagent.Human vertebral derived cells (HBV6408 passage 4) were 
trypsinized and resuspended in siPORT siRNA electroporation buffer (Ambion, Austin, 
TX) at a density of 1.8 X 107 cells/ ml. The cells were electroporated with 74 pmol of 
siCONTROL non targeting siRNA #1 or ON-TARGET plus NFIB Duplex 5 (Dharmacon 
J-008456-05) in 0.1 ml using a Bio Rad Gene pulse Xcell instrument and 2 mm cuvettes. 
The cells received a single 140 V square wave pulse of 15 ms duration. Total RNA was 
extracted at 24 and 48 h for qRT-PCR assay. MG63 cell lysates were collected at 72 h for 
protein analysis by western blot. To determine if overexpression of Nfib can reverse the 
effects of NFIB siRNA knockdown on IGFBP5 transcription, MG63 cells were 
trypsinized and resuspended in siPORT buffer at a density of 3 X107 cells/ ml. Cells were 
electroporated with 74 pmol of siCONTROL non targeting siRNA #1 or ONTARGET 
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plus NFIB Duplex 5 (Dharmacon J-008456-05) together with 2.5 μg of BP5p252-luc and 
2.5 μg of pCH-B (mouse Nfib) or pCH-parental plasmid using the same parameters as for 
normal vertebral cells. The single IGFBP5 siRNA duplex targets a sequence in 
endogenous human NFIB mRNA that is not present in mouse Nfib mRNA. Luciferase 
reporter activity was determined 48 h after electroporation. 
 
Electrophoretic Mobility Shift Assay (EMSA) 
Nuclear extracts were prepared from confluent MG63 and JEG-3 cells utilizing 
the Active Motif Nuclear Extract Kit, as per manufacturer’s instructions. A double 
stranded synthetic oligonucleotide corresponding to IGFBP5 promoter sequence bp -67 
to -34 containing the NFI binding site wt BP567-34:(5’-
GCAGCTACAAACTGGCTGGCAGCCAGGGGCCGG-3’) (Figure 5A), was labeled 
with dCTP[-32P] (111 Tbq/mmol, MP Biomedical), by fill in with DNA polymerase 
Klenow fragment (New England Biolabs). The gel shift reaction was performed with 10 
μg of nuclear extract protein using the Nushift™Kit (Active Motif) without addition of 
poly dI:dC. For supershift 5 μg HA.11 antibody (Covance), NFIB2 antibody (Active 
Motif) or Normal Rabbit IgG (Jackson ImmunoResearch) were incubated with nuclear 
extract for 20 min at 4°C prior to addition of IGFBP5 probe for 20 min. DNAprotein 
complexes were separated by electrophoresis on 5% polyacrylamide gels run in TGE 
(0.05M Tris, 0.4M Glycine, and 0.002M EDTA) buffer, pH 8.5 at 4°C. Complexes were 
imaged using a Storm 820 Phosphorimager (GE Healthcare Bio-sciences). 
In binding competition experiments increasing concentrations (2.5X, 5X, 10X and 20X) 
of unlabeled double stranded oligonucleotides were incubated with the nuclear extract 
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prior to addition of the [32P]-BP567-34 wt probe. Binding competitors were BP567-34 wt 
containing the NFI binding site, NFI consensus sequence (5’-
CAGCCTTTGGCATGCTGCCAATA-3’), BP567-34 mNFI with mutations in the NFI 
binding site (5’-GCAGCTACAA ACcttCTGGCAGtaAGGGGCCGGC-3’), BP567-34 
mAP2 with mutation of the AP-2 site (5’-GCAGC 
TACAAACTGGCTGGCAGCCAGGactaGGC-3’), and Col1a2 from the proximal 
promoter of the human type I α2 procollagen gene, containing no NFI binding sequences 
(NCBI Gene symbol COL1A2, 5’-CCTCCTCTGCGCCCCCGCAGG 
CTCCTCCCAGCTGTG GCT-3’). 
 
Chromatin Immunoprecipitation (ChIP) 
MG63 cells were formaldehyde fixed and chromatin DNA complexes were 
enzymatically sheared using a ChIP-IT™ Express Enzymatic Kit (Active Motif). 
Chromatin was immunoprecipitated with 3 μg of mouse NFI-B2 or Negative Control 
Rabbit IgG (Active Motif). PCR with precipitated chromatin and input DNA templates 
was performed with 2X GoTaq Master Mix (Promega) using primer pairs for the IGFBP5 
gene bp -119 to + 54 (For: 5’-GGCATCCTTGCCTGAGTTG-3’, Rev: 5’-
CTGCTTTGCAGCTCTTTCCTA-3’) and for two negative controls, NFI-X coding 
sequence (Exon 4 – 6, For: 5’-CCACTGCCCAACGGACACTT-3’, Rev: 5’- 
CCGGGATAGAACACGTCATCA -3’) and GAPDH gene proximal promoter (For: 5’-
TACTAGCGGTTTTACGGGCG-3’, Rev: 5’-TCGAACAGGAGGAGCAGAGAGCGA-
3’). To compare relative amounts of IGFBP-5 promoter amplicons precipitated by NFIB2 
and control antibodies, the precipitated chromatin DNA was amplified by real time PCR 
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from duplicate precipitated chromatin samples of each, using the same IGFBP5 promoter 
primers and SYBR as described for RT-PCR. 
 
Western Blots 
MG63 cells were lysed in RIPA Buffer containing protease inhibitors (Sigma). 
Extracts (20 μg protein) were assessed with NFIB2 (Active Motif), IGFBP5 (Santa Cruz 
Biotechnology Inc., Santa Cruz, CA), HA.11 (Covance, Emeryville, CA), and Actin 
(Sigma, St. Louis, MO) primary antibodies followed by IRDye secondary antibodies. 
Bands were imaged with an Odyssey Infrared Imaging system (Li-Cor). 
 
Statistical Analysis 
All of the statistical analyses were performed using the Microsoft Excel data 
analysis program for Student’s t test analysis with an assigned significance level of p < 
0.01. All of the experiments were repeated at least three times. The values are expressed 
as the means ± SEM. 
 
Results 
Nuclear Factor I mRNA Expression in Osteoblasts and Osteoblast-like Cells 
We sought to determine the potential roles of NFI transcription factors in 
regulation of IGFBP5 transcription in human osteoblasts. As a first step, the relative 
mRNA expression levels of NFIA, NFIB, NFIC and NFIX genes were determined in early 
passage subconfluent cultures of human osteoblasts and osteoblast-like cell lines using 
qRT-PCR (Table 2). RT and realtime PCR reactions were performed under conditions in 
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which relative mRNA levels are linearly proportional to RNA input. NFIC mRNAs were 
consistently the most abundant in each cell sample, therefore these were used as baseline 
for the quantification of relative expression of the other NFI genes. The NFIC ΔCt values 
ranged from 6.3 (U2OS) being the most abundant to 8.51 (MG63) the least abundant, 
with a difference of 4 fold in relative expression levels. Although NFIC was the most 
highly expressed gene in the majority of cell lines, in MG63 osteoblast-like cells NFIB 
mRNA levels were 16 fold higher than NFIC levels. NFIA mRNA levels were least 
abundant in all cell samples except the normal osteoblasts and U2OS cells in which NFIX 
expression was also low. These data suggested that NFIB and NFIC might have the most 
important roles in regulating IGFBP5 transcription in human osteoblast cells. 
 
NFI Transcription Factors Modulate IGFBP5 Promoter Activity 
We examined the effects of NFI proteins on IGFBP5 promoter activity by 
transiently co-transfecting MG63 and TE85 cells with mouse Nfi expression vectors 
(pCH-A, pCH-B, pCH-C and pCH-X) and a promoter construct containing bp -252 to 
+24 of the human IGFBP5 gene in pGL3.1 luciferase reporter (BP5-p252-luc) as 
described [23]. Nfib was the most active in stimulating IGFBP5 promoter activity (Figure 
3A, 3B), and showed a biphasic dose response in TE85 cells with maximal stimulation of 
approximately 10 fold. Western blot from a representative experiment indicates that all 
four Nfi genes were expressed after transfection (Figure 3C). Human NFIB2 was as 
effective as mouse Nfib2 in stimulating IGFBP5 transcription (Figure 3D). Nfix was less 
active than Nfib and increased promoter activity with dose dependent maximal 3 fold 
stimulation in TE85 cells (Figure 3A). Nfia and Nfic modestly increased IGFBP5 
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promoter activity at lower doses and inhibited promoter activity at the higher doses 
tested. The effect of Nfic on IGFBP5 promoter activity was surprising since its relative 
mRNA expression was high in both early passage human osteoblasts and osteoblast-like 
osteosarcoma cells. In contrast to TE85 cells, fold activation of the IGFBP5 promoter by 
Nfib and Nfix was less in MG63 cells (Figure 3B), possibly because high endogenous 
expression of NFIB in this cell line already supported strong basal promoter activation, 
and increased the sensitivity to inhibition by exogenous Nfi expression. 
 
  
Table 1. Primer sequences utilized in qRT-PCR.  mRNA levels were assessed by 
reverse transcriptase cDNA synthesis using random primers, followed by real-time 
PCR using the primers listed and SYBR Green quantitation 
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Table 2. Human  NFI  family gene expression in human osteoblasts 
and osteoblast-like cell lines. Relative mRNA levels for each NFI  
family were estimated by qRT-PCR using primers in Table 1.  Each 
value of ΔCT (ΔCT  NFI gene - CT  GAPDH ) is average of at least 3 
determinations. Abundance  relative to NFIC in each cell type was 
determined by the 2-ΔΔCT Method [43].  NFIC was the most abundant 
mRNA in all cells except MG63, in which NFIB was highly expressed. 
32 
 
 
 
33 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Effects of Nfi family transcription factors on IGFBP5 promoter activity. Cells 
were cotransfected with 0.5 μg of BP5-252-Luc promoter luciferase reporter and the 
indicated amounts of mouse Nfia, Nfib, Nfic, or Nfix HA tag expression vector DNA, or 
empty expression vector. A) TE85 cells B) MG63 cells. Promoter activity determined as 
luciferase light units/protein is expressed as fold activation compared to control activity 
(co-transfection of empty expression vector), mean ± SEM n = 6 replicates. Data from 
each graph are representative of one experiment, which was repeated two or more times. 
C) Western blot with HA antibody of 20μg of MG63 whole cell lysates transfected with 
each NFI expression vector demonstrates expression of the transgenes, and is similar to 
those previously published [45, 46]. The 51 kDa band is non-specific, and is present in 
non-transfected control cell extracts. D) TE85 cells were co- transfected with BP5-252-
Luc and the indicated amounts of mouse Nfib or human NFIB expression vector DNA, or 
empty expression vector. * indicates significantly different from control (p<0.01). 
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Effects of NFI siRNA Transfection on NFIB and IGFBP5 Expression 
Levels 
To complement the NFI overexpression and IGFBP5 promoter activity 
experiments, siRNA was used to determine if knockdown of endogenous NFIB 
expression would decrease IGFBP5 expression. MG63 cells were transiently transfected 
with 200 pmol of non-targeting control siRNA or a pool of 50 pmol each of 4 different 
siRNAs targeting human NFIB. Analysis of mRNA levels by qRT-PCR indicated that 
NFIB mRNA levels were significantly reduced by 60% and 70% at 24 and 48 h 
respectively, compared to non-targeting control (Figure 4A, p<0.01). NFIB protein 
expression was also reduced by 76% at 72 hours post transfection (Figure 4B). 
Importantly, IGFBP5 expression was also inhibited by 50% and 55% at 24 and 48 h after 
transfection with NFIB siRNA, and IGFBP5 protein levels were inhibited 33% at 72 h 
compared to the control (p<0.01). To determine whether knockdown of NFIB expression 
also reduces IGFBP-5 expression in non-transformed human osteoblasts, vertebral bone 
derived cells were transfected with non-targeting or NFIB targeting siRNA using 
electroporation. NFIB mRNA levels were significantly reduced by 96 % at 48 h, 
compared to non-targeting control and IGFBP5 mRNA levels were reduced by 63 % 
(Figure 4A). NFIC and NFIX mRNA levels in MG63 cells did not significantly change 
when NFIB expression was inhibited by siRNA (Figure 4A). Similar results were 
obtained with 200 pmol of individual NFIB siRNAs compared to the mixture (data not 
shown). 
Because NFIC was highly expressed in human osteoblasts and was apparently 
inhibitory to the IGFBP5 promoter activity, we determined whether knocking down 
NFIC expression would affect NFIB and IGFBP5 mRNA levels. MG63 cells were 
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transfected with a specific pool of siRNAs targeting human NFIC, (Figure 4C) resulting 
in a decrease in NFIC mRNA expression of 90% (p<0.01). NFIC knockdown increased 
IGFBP5 mRNA levels 1.6-fold (p<0.01), but did not significantly affect NFI-B mRNA 
levels. NFIX siRNA knockdown reduced NFI-X mRNA levels 90 %, but did not 
significantly affect IGFBP5 or NFI-B mRNA levels (Figure 4C). These results are 
consistent with IGFBP5 promoter experiments showing that NFIC inhibited IGFBP5 
transcription. 
While use of an optimized mixture of gene targeting SMART pool siRNAs 
minimizes non-specific off-target effects [47], to further confirm the specificity of NFIB 
siRNA knockdown, we performed a rescue of function experiment as a control for off 
target effects [48]. Mouse Nfib was overexpressed to counteract effects of endogenous 
NFIB knockdown on IGFBP5 promoter activity. MG63 cells were cotransfected by 
electroporation with non-targeting siRNA or a siRNA duplex targeting endogenous 
human NFIB that does not target mouse Nfib, plus BP5-p252-luc and pCH-B mouse Nfib 
expression vector or pCH empty vector (Figure 4D). IGFBP5 promoter activity was 
determined after 48 h. In cells transfected with siRNA targeting NFIB, and control pCH 
vector, BP5-p252-luc promoter activity was decreased by 74% compared to the control 
group that contained the non- targeting siRNA (p<0.01). Effects of siRNA on promoter 
activity were thus similar to effects on IGFBP5 mRNA levels. Overexpression of mouse 
Nfib increased IGFBP5 promoter activity in cells receiving NFIB-targeting siRNA by 
approximately 2 fold (p<0.01). This rescue of the effects of NFIB siRNA on IGFBP5 
expression supports the conclusion that the siRNA knockdown was not the result of off 
target siRNA effects. 
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NFIB Activation of IGFBP5 Promoter Deletion and Mutation 
Constructs 
To identify elements of the IGFBP5 promoter region between bp -252 and +24 
that are involved in NFI- mediated transactivation, we created a series of IGFBP5 
promoter deletion constructs beginning at different 5’ positions (Figure 5A). Results 
indicated that basal promoter activity and activation of IGFBP5 promoter by Nfib in 
TE85 cells progressively decreased as 5’ regions of the promoter were deleted (Figure 
5B). Internal deletion of bp-70 to -35 from BP5p252-Luc strongly decreased basal 
promoter activity, but it did not completely abolish Nfib mediated activation (Figure 5B). 
These results suggest that while the proximal promoter region containing the putative 
NFIB binding site mediates significant regulation of promoter activity and NFI 
responsiveness, upstream cis-acting elements may also contribute to Nfib activation. 
Subsequent experiments focused on the proximal promoter region bp -106 to +24, 
containing the palindromic consensus NFI binding site sequence TGGC(N)5GCCA [43], 
adjacent to other cis elements that were previously reported to participate in modulating 
IGFBP5 gene transactivation [28, 33-36]. Deletion of the overlapping NFI/AP-2 binding 
site sequence in the BP5p106- Luc construct (BP5p106m1 in Figure 5A) or mutation of 
two bases in the 5’ side of the NFI binding sequence, without altering the 3’ side that 
overlaps the AP-2 site (BP5p106m2), strongly inhibited Nfib activation of promoter 
activity in both TE85 and MG63 cell lines (Figure 5D and Figure 5E). Mutation of one 
base in the 5’ side and one base in the 3’ side of the NFI binding sequence (BP5p106m3) 
decreased Nfib activation of the promoter, although not as strongly. 
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Figure 4.  Effects of NFI siRNA transfection on NFIB and IGFBP5 mRNA levels. MG63 
cells were transfected in with 200 pmol of non-targeting siRNA or Smart Pool siRNA 
targeting NFIB, NFIC or NFIX. Normal vertebral bone derived osteoblasts (HBV6408) 
were transfected by electroporation with 74 pmol of non targeting siRNA or siRNA 
duplex 5 targeting NFIB A) NFIB siRNA. Relative mRNA levels were quantified by 
qRT-PCR at 24 or 48 h. NFIB and IGFBP5 mRNA levels were significantly decreased in 
the NFIB siRNA groups compared to non-targeting control (* p <.05) but NFIC and 
NFIX mRNA levels were not changed. B) NFIB siRNA. NFIB and IGFBP5 protein 
levels were detected by Western Blot 72 hours post transfection as in A. C) NFIC or 
NFIX siRNA. NFIC and NFIX mRNA levels were significantly decreased by respective 
siRNAs. IGFBP5 mRNA levels were significantly increased by NFIC siRNA, but not by 
NFIX siRNA. NFIB mRNA levels not significantly affected by NFIC or NFIX siRNA. 
D) Effects of mouse Nfib expression rescue on IGFBP5 expression were determined by 
assessing IGFBP5 promoter activity. MG63 cells were co-transfected by electroporation 
with 74 pmol of non-targeting or NFIB targeting siRNA (single siRNA duplexes) plus 
2.5 μg of BP5p252-Luc reporter plasmid and 2.5μg of either Nfib expression vector or 
control vector. Mouse Nfib mRNA was not targeted by the human NFIB siRNA duplex. 
IGFBP5 promoter activity was determined at 48 hours (n = 6 wells per group). Relative 
mRNA levels and promoter activities in all groups are reported as % of the non-targeting 
siRNA group. * = significantly different from non-targeting siRNA, p < 0.01; In C, # = 
significantly different from control expression vector, p < 0.01. 
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Figure 5. NFIB activation of IGFBP5 promoter activity in promoter deletion and 
mutation constructs. A) Cis elements in the human IGFBP5 promoter, sequences of 
proximal promoter containing NFI and AP-2 sites, and deletion and mutant sequences 
tested in BP5p106-Luc. B) TE85 cells were co-transfected with 0.25 g pCH control or 
pCHB Nfib expression plasmid plus 0.5 g of promoter reporter BP5-252-Luc, 5’ 
deletions (p124, p106, p70) or bp –35 to –70 deletion in BP5-252-Luc. C), D) TE85 and 
MG63 cells were transiently co-transfected with 0.5 g of wt, m1, m2 and m3 BP5p106-
luc constructs and 0.25g of pCH control or Nfib HA tag expression vector. Altered 
nucleotides in m2 and m3 are indicated in lower case. 
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NFIB Binds to the IGFBP5 Promoter Region 
In order to establish if NFIB activation of IGFBP5 transcription was mediated by 
direct binding to the consensus binding sequence in the proximal promoter, we performed 
Electrophoretic mobility shift assays (EMSA) and Chromatin Immunoprecipitation 
(ChIP) assay. Nuclear extracts were made from the MG63 cell line, because it contains 
high endogenous NFIB mRNA and protein levels. Nuclear extract formed a major 
complex with the BP567-34 probe containing putative binding sequences for NFI as well 
as AP-2, and probe binding was competed by excess unlabeled wild type BP567-34 
oligonucleotide (Figure 6A, lanes 3-6). Unlabeled BP567-34 oligonucleotide containing 
mutations in the NFI binding site (lane 8-11), and an unrelated alpha 2 (I) collagen 
oligonucleotide competitor, not containing any consensus NFI cis elements (lane 12), did 
not compete with the BP567-34 probe. Addition of an alternative NFI consensus 
oligonucleotide competitor, not identical to the probe sequence, and BP567-34 
oligonucleotide competitor with mutation of the AP-2 binding site, not overlapping the 
NFI site, also reduced probe binding to the nuclear protein complex (data not shown). To 
determine if NFIB was present in the probe-nuclear protein complex, NFIB2 antibody 
was added to the reaction mixture. NFIB2 antibody, but not control normal rabbit IgG, 
produced a supershift (Figure 6B), indicating that NFIB indeed binds to the putative 
binding site in the proximal IGFBP5 promoter. 
Due to unavailability of specific antibodies to NFIA, NFIC and NFIX proteins for 
use in EMSA, supershift experiments for these endogenous NFI proteins could not be 
done. To determine if these proteins bind to the IGFBP5 proximal promoter region 
containing the NFI site, binding of HA-tagged Nfia, Nfib, Nfic, and Nfix to the BP567-34 
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probe was tested using the human choriocarcinoma cell line JEG-3, which expresses low 
levels of endogenous NFI proteins [46]. JEG-3 cells were transiently transfected with 
pCH-A, pCH-B, pCH-C, or pCH-X and nuclear extracts were tested by EMSA. Nuclear 
extracts from cells transfected with all four HA-tagged NFI proteins formed complexes 
with the BP567-34 probe (only Nfib is shown, Figure 7 lane 4), but nuclear extracts from 
JEG-3 control cells transfected with pCH empty control vector did not (lane 3). Addition 
of HA antibody produced a supershift with nuclear extracts from cells transfected with 
each of the Nfi expression vectors (lanes 5-8), as previously demonstrated with a probe 
from a well characterized NFI binding site consensus sequence [49]. This data shows that 
all four Nfi transcription factors bind to the NFI cis element in the IGFBP5 proximal 
promoter. NFIB binding to the IGFBP5 promoter in vivo was assessed utilizing the ChIP 
assay. Sheared MG63 chromatin was immunoprecipitated with NFIB2 polyclonal 
antibody. PCR was performed on the precipitated DNA fragments by using specific 
IGFBP5 promoter primers to amplify fragments of approximately 150 bp. We found that 
PCR amplification of the proximal IGFBP5 promoter region with DNA template 
chromatin precipitated by the NFIB2 antibody produced a strong band, while chromatin 
precipitation with a control rabbit IgG did not (Figure 8). Relative amounts of IGFBP5 
promoter DNA precipitated by NFIB specific antibody and control IgG were compared 
by real-time PCR with the same primers. A difference of 3.0 cycles was observed 
between CT values, corresponding to 8 fold higher abundance in the NFIB specific ChIP 
complex. Negative control primer sets amplifying exon 4-6 of the NFIX gene and 
GAPDH proximal promoter were used to determine specificity of chromatin 
precipitation. Both GAPDH promoter and NFIX coding region were amplified from input 
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DNA, but not from DNA precipitated by NFIB2 antibody or control IgG. These 
experiments corroborate data from in vitro binding of NFIB to the IGFBP5 promoter in 
EMSA experiments. 
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Figure 6. Endogenous NFIB binds in vitro to a NFI binding site in the IGFBP5 proximal 
promoter region. Equal amounts of double stranded BP567-34 oligonucleotide probe 
were incubated with 7 g of MG63 nuclear extract (NE). DNA-protein complexes were 
resolved in 5% polyacrylamide gels and analyzed with a Storm Phosphorimager. A) 
Increasing amounts (2.5X, 5X, 10X, and 20X) of BP567-34 wt and NFI mutant (BP567-
34 mNFI) or 20 fold excess of unrelated α 2 (I) collagen (Col) unlabeled competitors 
(Comp) were added to the reaction. B) Equal amounts (5 g) of NFIB2 and non-immune 
IgG (IgG) antibodies (Ab) were added to the probe/nuclear extract reaction. Arrow: 
supershifted complex. Lanes 1-3 and lanes 5-6 were separated by other samples on the 
same gel and were joined to produce this figure. 
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Figure 7. Nfi proteins bind in vitro to the IGFBP5 proximal promoter. JEG-3 cells were 
transfected with mouse Nfia, Nfib, Nfic, or Nfix HA tag expression vectors, or empty 
control vector. 10 μg of nuclear extract from each transfection were incubated with 
BP567-34 probe plus anti-HA antibody or non-immune control (IgG) as indicated. 
Protein-DNA complexes were analyzed as in Figure 4. As shown in lanes 2 and 3, JEG-3 
cells have very low endogenous NFI/AP-2 binding to the probe. 
 
 
48 
 
 
 
 
 
 
 
 
 
49 
 
 
 
 
 
 
 
 
 
Figure 8. NFI proteins bind in vivo to the IGFBP5 proximal promoter. Formaldehyde-
fixed MG63 chromatin (6 μg) was precipitated with 3μg of non-immune IgG1 (lane 1) or 
NFIB2 (lane 3) antibodies and the precipitated DNA was analyzed by PCR. Equal 
amounts of input chromatin DNA were also amplified (lane 2). Amplicons stained with 
ethidium bromide are shown as negative images. IGFBP5 proximal promoter primers 
amplified a product from DNA precipitated by NFIB2 antibody which was 8 fold more 
abundant in NFB2 compared to non-immune IgG ChIP as determined by quantitative real 
time PCR of duplicate samples. Negative control primers that target the human NFIX 
exon 4 - 6 coding sequence or the human GAPDH proximal promoter only produced PCR 
products from input DNA templates. 
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Discussion 
In the present study we demonstrated that all four Nfi proteins can bind to the 
IGFBP5 proximal promoter region containing a NFI binding site. Murine Nfib and Nfix 
increased IGFBP5 promoter activity in a biphasic manner with Nfib being the most 
active, while Nfia and Nfic modestly increased, but mostly decreased promoter activity 
depending on amount of expression vector used. Results of Nfib and Nfic expression on 
promoter activity were corroborated by siRNA mediated gene knockdown experiments in 
which knockdown of endogenous NFIB expression decreased IGFBP5 mRNA and 
protein levels and decreased IGFBP5 promoter activity, while NFIC knockdown 
increased IGFBP5 expression. Relative expression levels of the four NFI genes, and 
effects of each on transcription of different target genes varies between species and cell 
type [43]. We found that the NFIC gene was the most highly expressed based on mRNA 
levels in non-transformed normal human osteoblasts and osteoblast-like cell lines, except 
in the MG63 cell line where NFIB was highly expressed. The PCR primers for NFIB 
could amplify NFIB1 and NFIB2 that are produced by alternate mRNA splicing in 
mouse, but not NFIB3 which is truncated after the DNA binding domain [43]. NFIB1 
isoform expression has not been reported in human cells, and NFIB3 isoform had very 
low expression levels in MG63 cells by qRT-PCR with NFIB3 specific primers (data not 
shown). NFIC relative expression was highest in all three normal human osteoblast 
cultures, while NFIX and NFIA expression were lowest, which is similar to expression 
patterns in the TE85 and U2OS cell lines. While expression levels of NFIA, NFIB and 
NFIX varied between each of the three normal cell preparations, correlation of these 
differences with osteoblastic phenotype, or with tissue donor sex and age was not 
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apparent. Observation that siRNA knockdown of NFIB had similar effects on IGFBP5 
expression in MG63 cells and normal vertebral bone derived cells suggests that the role 
of NFIB is similar in normal osteoblastic cells and cells that have undergone tumor 
transformation and immortalization. 
Comparison of the effects of Nfib and Nfic on IGFBP5 promoter activity, and 
effects of NFIB and NFIC siRNA on expression of IGFBP5, suggest that they could have 
opposing effects on IGFBP5 transcription. The relative abundance of these and the other 
NFI gene products could play a significant role in modulating IGFBP5 expression levels 
in osteoblasts and other cell types. Knockdown of NFIB by siRNA did not increase 
expression of NFIC and NFIX mRNA levels, and knockdown of NFIC or NFIX did not 
alter NFIB expression, suggesting that there may not be compensation of expression 
among the four genes. NFI proteins resulting from expression of the four genes and 
alternate mRNA splicing have been reported to have diverse relative effects on different 
gene promoters and in different cell types [43, 50-53]. Heterodimer formation between 
NFIB and other NFI family members may produce different effects depending on the 
associated NFI proteins [43]. Differential expression, mRNA splicing and heterodimer 
formation likely function to integrate diverse biological signals in modulating NFI effects 
on expression of IGFBP5, other genes and associated cellular functions. 
EMSA and ChIP experiments support the conclusions from the functional assays 
of mutant promoter constructs that NFIB transactivates the promoter by binding to the 
NFI consensus binding site in the IGFBP5 proximal promoter region. However, deletion 
of bp -70 to -35 in the BP5-p25270-35-Luc construct did not completely prevent NFI 
activation, suggesting that, in addition to the NFI site at bp -55 to bp -42, sequence 
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elements upstream of the NFI site may also be involved in mediating activation of the 
promoter. The NFI binding site overlaps an AP-2 site (bp -46 to -37), previously 
demonstrated to mediate promoter activation by AP-2α [34] A previous study found that 
mutation of the overlapping sequence reduced basal IGFBP5 promoter activity in rat 
osteoblasts, while mutation of the AP-2 site alone did not, but effects of NFI 
overexpression or siRNA knockdown on IGFBP-5 promoter activity were not 
investigated [35]. The present study provides more direct evidence that the NFI site does 
function in transcriptional regulation. Whether NFI and AP-2 interact directly in 
regulation of IGFBP5 promoter activity remains to be determined. A Myb binding site on 
the 5’ side of the NFI site (bp -60 to – 56) was reported to mediate some, but not all 
activation of the IGFBP5 promoter by c-Myb and B-Myb in neuroblastoma cells. The 
Myb response element was also reported to mediate inhibition of IGFBP5 promoter 
activity in fetal rat osteoblasts by BMP-7 and cortisol [31, 32]. However, we found that 
deletion of the NFI site, leaving the Myb site intact, abolished NFI activation, suggesting 
that activation of IGFBP5 promoter by NFI does not involve the adjacent Myb response 
element. However, the results do not rule out potential interactions between NFI and 
Myb, C/EBP, AP-2 or other transcription factors. 
Competition of AP-2 and NFI for the overlapping binding site, for example, may 
be important in modulating IGFBP5 gene transactivation, and is being investigating in 
ongoing studies. 
NFI transcription factors have been implicated in diverse cellular and molecular 
processes. For instance, NFI proteins stimulate initiation of adenovirus DNA replication 
[43], and have been associated with the regulation of many genes including cyclin-
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dependent kinase inhibitor 1A (p21), TR2 orphan receptor, alpha 1 (I) collagen, p53, 
whey acidic protein (WAP), and GLUT4 [52, 54-58]. NFI proteins functionally interact 
with and/or bind other TFs and co-activators including GR, AP-2, SRC-1 and CBP/p300 
[35, 45, 59]. 
Recent studies indicate that NFI plays important roles during bone development 
and chondrocyte differentiation. Nfix deficient mice displayed severe growth retardation 
and deformation of the spine that was associated with delayed endochondral ossification 
and decreased mineralization [42], although the growth retardation was reduced in 
another study by feeding a soft diet [41]. Nfic deficiency in mice inhibited odontoblast 
differentiation and tooth root development [39, 40]. Nfib overexpression in murine 
mesenchymal (ATDC5) cells transactivated the murine alpha 2 (1) collagen promoter, 
suggesting that this transcription factor is involved in the early stage of chondrocyte 
differentiation [60]. In contrast, Nfia overexpression was reported to repress 
Runx2/Cbfa1 promoter activity in rat osteosarcoma cells by a mechanism involving an 
osteoblast specific enhancer region, while the other NFI family members had no effect on 
activity [61]. 
Observations of the present study suggest that NFIB modulation of IGFBP5 
expression in human osteoblasts may have a role in support or regulation of osteoblast 
proliferation and differentiation, given that IGFBP5 is an important modulator of these 
events [8]. IGFBP5 stimulated osteoblast proliferation and differentiation in vitro and 
bone formation in vivo. For example, human IGFBP5 protein increased alkaline 
phosphatase activity and osteocalcin expression [13] in MG63 cells and increased 
proliferation in mouse calvaria cells [13]. In vivo studies found that systemic 
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administration of IGFBP5 to rats increased the effects of IGF-I to stimulate calvaria bone 
formation [62], and IGFBP-5 treatment of mice increased serum osteocalcin levels (bone 
formation marker) and femoral bone ALP activity [13]. IGFBP-5 actions on osteoblast 
differentiation and bone formation were found, in part, to be IGF independent. IGFBP-5 
stimulated proliferation and alkaline phosphatase activity of mouse osteoblasts from IGF 
I knockout mice, in which IGF I and IGF II production were undetectable, and in vivo 
IGFBP5 injection increased parietal bone alkaline phosphatase activity [11]. However, 
other studies reported that overexpression of IGFBP5 in transgenic mice [63, 64] or by 
viral vector expression in cultured osteoblasts inhibited osteoblast differentiation [65]. 
These inhibitory IGFBP5 actions may arise from inhibition of IGF activities by high 
extracellular IGFBP5 concentrations [3, 66, 67], while other actions of IGFBP-5 may be 
mediated by intracellular mechanisms [8, 12, 22, 68]. Yin et al. for example found that 
siRNA inhibition of IGFBP-5 expression increased apoptosis in U2OS cells and that 
IGFBP5 expression from a viral vector reduced apoptosis while addition of extracellular 
IGFBP5 protein did not [68]. It is possible that NFI and other transcription regulators 
modulate intracellular IGFBP5 levels and activities while external factors such as blood 
levels, extracellular matrix and proteases function more to modulate extracellular 
IGFBP5 levels to provide a complex balance between stimulatory and inhibitory IGFBP5 
actions on osteoblasts and othercells. 
In summary, we report novel evidence for IGFBP5 transcriptional regulation by 
NFI proteins in human osteoblasts. NFIB activates IGFBP5 promoter mainly through 
direct binding to a response element in the proximal promoter, although interaction with 
other cis-acting elements upstream of this sequence may also play a role in NFI 
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regulation of IGFBP5 promoter activation. These results suggest that differential 
regulation of IGFBP5 expression by NFI gene family transcription factors may 
besignificant to modulation of osteoblast proliferation and differentiation. 
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CHAPTER THREE 
 
REGULATION OF MURINE OSTEOBLAST DIFFERENTIATION 
BY NUCLEAR FACTOR I 
 
Abstract 
Bone formation is a complex process that requires a wide array of molecules in 
order to properly occur. Mesenchymal stem cells, which can be differentiated into 
adipocytes, myoblasts, fibroblasts and chondrocytes, can also give raise to osteoblasts 
under the activation of osteoblastic factors. Previous in vitro studies have shown that the 
transcription factor family NFI, regulates the mRNA expression of IGFBP5, stimulator of 
osteoblast proliferation and differentiation, in human osteoblasts. Moreover, the knockout 
Nfix model displays impaired endochondral ossification. We evaluated the role of the Nfi 
gene family in osteoblast differentiation using the MC3T3-E1 preosteoblast in vitro 
model for osteoblast differentiation. Nfix mRNA levels increased during MC3T3-E1 
osteoblast differentiation induced by ascorbic acid and β-glycerophosphate.  Stable 
knockdown of  Nfix in MC3T3-EI cells was accomplished using lentiviral shRNA 
vectors.  Cells stably transduced with a validated shRNA vector targeting Nfix or a non-
targeting shRNA vector grown in differentiation media were observed to have delayed 
mineralization compared to control cells. mRNA transcript levels of osteocalcin (Ocn), 
bone sialoprotein (Bsp) and Runt-related transcription factor 2 (Runx-2) were 
significantly decreased in Nfix deficient calvarial osteoblasts. Promoter-luciferase 
reporter assays also showed that transient transfection of MC3T3-E1 cells with a plasmid 
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Nf1x expression vector significantly increased activation of the murine OCN promoter. 
Results suggest that Nfix has a critical role in osteoblast differentiation, perhaps through 
direct effects on expression of osteoblast specific genes such as osteocalcin.  
 
Introduction 
Osteogenesis 
 The bone formation process is a very complex one and requires several signaling 
pathways. Osteoblasts, arise from mesenchymal stem cells (MSCs) which can also give 
rise to, adipocytes, myoblasts, fibrous tissue forming cells, and chondrocytes  (Krebsbach 
et al., 1999). The osteoblastogenesis process requires a wide array of signaling proteins 
including hormones, cytokines, growth factors, and extracellular matrix proteins. 
Appropriate stimulation of signaling pathways determines the commitment and fate of 
the MCSs into osteoblasts. Among the most relevant molecules controlling osteoblast 
differentiation are Runx2 (Cbfa1/AML3) and Osterix transcription factors, and 
extracellular regulators bone morphogenetic proteins (BMPs), Wnts and insulin like 
growth factors (IGFs) (McCarthy et al., 2000)   
Runx2 and its downstream signaling molecule, osterix (OSX) function to activate 
osteogenic genes that are required for proper bone matrix synthesis (Ducy, 2000) . 
The process of osteoblast differentiation involves three main characteristic stages that are 
characterized by the transcriptional regulation of osteoblastic genes at each particular 
stage: proliferation, extracellular matrix development and lastly mineralization. Some of 
the standard markers utilized to determine osteoblast lineage differentiation are Bsp and 
Ocn.  
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Nuclear Factor I 
 Previous experiments in human osteoblasts have shown that the NFI TF family is 
involved in regulating expression of IGFBP5, a protein that enhances IGF activities and 
bone formation.. Vertebrate NFI TFs comprise a family of closely related proteins, NFIA, 
NFIB, NFIC (originally identified as CTF-1), and NFIX. Gene knockout studies of NFI 
have shown that Nfia -/- mice display mainly neuroanatomical defects (Shu et al., 2003), 
Nfib-/- mice show lung and brain defects (Steele-Perkins et al., 2005), Nfic knockout 
caused primarily a disruption of tooth root and underlying mandibular bone development 
(Steele-Perkins et al., 2003). Nfix-/- mice were first reported to have brain malformation 
and severe kyphosis, due to impaired endochondral ossification. Transcriptional 
regulation by the four NFI gene members varies depending on cell type and gene 
promoter. NFIA inhibited Cbfa1/Runx2 promoter activity specifically in mouse fibroblast 
cell lines, and by its absence in osteoblasts was proposed to allow osteoblast specific 
expression (Zambotti et al., 2002) endochondral ossification and decreased 
mineralization in the vertebrae and long bones (Driller et al., 2007).    
 The purpose of this study is to determine the effects of Nfix gene knockdown on 
MC3T3-E1 induced differentiation.  
 
Materials and Methods 
Cell Culture 
MC3T3-E1 cells (a gift from B. Frenkel,University of Southern California 
(Luppen et al., 2003) were maintained in αMEM supplemented with 10% fetal bovine 
serum. To induce differentiation, the media was supplemented with 50 μg/ml ascorbic 
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acid and 10 mM β-glycerophosphate (osteogenic media). Media was changed every 2-3 
days and cells were maintained in osteogenic media for 14-21 days to induce 
differentiation. 
 
RNA Extraction and Quantitative RT-PCR 
Three independent samples of total RNA per group were isolated from MC3T3-
E1 cells beginning 1 day after 80 % confluent cells were changed to osteogenic media, 
using a Gentra Systems Versagene™ kit (Fisher Scientific).  300 ng RNA from each 
sample were reverse transcribed in duplicate using SuperScript III (InVitrogen) or iScript 
(BioRad).  Real time PCR was performed with an Opticon 2 Fluorescent Detector (MJ 
Research/BioRad), using SYBR Green Master Mix (Qiagen) and sequence specific 
primers for murine Nfia, Nfib, Nfic, Nfix, OCN, BSP, Runx2, OSX and PPIA (Table 3). 
PCR primers and other oligodeoxynucleotides were from Integrated DNA Technologies 
Inc. Relative mRNA levels were determined using the 2-ΔΔCt method, as described (Perez 
et al., 2009) and were normalized to endogenous PPIA mRNA levels.  These values were 
expressed relative to Nfia mRNA levels in the first time point in each cell line or relative 
to non-targeting control in siRNA knockdown experiments.  
 
Short Hairpin Lentiviral Transduction 
A set of 5 lentiviral MISSION shRNA vectors targeting different sequences in 
mouse Nfix was obtained as viral particles from Sigma Chemical Co. (St. Louis, MO).  
The viral constructs produce shRNA that is processed to active siRNA within the target 
cells, and also express a Puromycin resistance gene.  MC3T3-E1 cells were separately 
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transduced at an MOI of 10 with each Nfix targeting viral vector and a validated non-
targeting shRNA lentiviral vector.  Cells were selected 3 days in Puromycin, and 
expanded without puromycin, and replicates of each line were used for RNA extraction 
and assessment of Nfix mRNA levels by qRT-PCR.  One of the lentiviral constructs 
(TRCN0000075349) that targets a sequence in Exon 3 reduced Nfix mRNA levels by 
80% so these cells were grown further.  The cells maintained strong Nfix mRNA 
knockdown after multiple passage and cryopreservation.  
 
Luciferase Reporter Assay 
MC3T3-E1 cells were transiently transfected at 50% confluency in 6 well plates 
with 0.5 μg of OCN promoter-Luc plasmid DNA and 0.125 to 1μg of each murine Nfi 
plasmid expression vector (Boonyaratanakornkit et al., 1999a; Chaudhry, Lyons, & 
Gronostajski, 1997; Mukhopadhyay et al., 2001) using TurboFectin 8.0 (OriGene 
Technologies). Total plasmid DNA was adjusted by addition of pCH empty expression 
vector. MC3T3-E1 culture medium was changed to 1mg/ml BSA in DMEM after 18 h, 
cells were extracted in reporter lysis buffer (Promega) after an additional 24 h, and 
luciferase activity was determined as described(Boonyaratanakornkit et al., 1999a). 
Luciferase activities were normalized to protein concentrations determined by 
bicinchoninic acid (BCA) assay (PierceBiotechnology) and are presented as fold of 
control. Sample groups consisted of 6 replicate wells of cells.  
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Alizarin Red-S Staining 
Alizarin red staining was used to assay mineralized nodule formation at days 18 
and 21. Briefly cells were fixed for 30 min in 100% methanol for 30 min at -20°C, 
washed with PBS three times, stained with 40 mM Alizarin Red-S (Sigma-Aldrich, St. 
Louis,MO) pH 4.2 for 15 min at room temperature, washed with distilled water five 
times, rinsed in 1X  PBS for 10 min to reduce nonspecific staining, and dried overnight. 
The intensity of red staining and nodule formation was evaluated by optical density 
scanning at 510 nm using a Biotek Synergy 2 plate reader that determines absorbance in 
2000 circular spots covering 90% of the 9.4 cm2 well surface. 
 
Statistical Analysis 
All of the statistical analyses were performed using the Microsoft Excel data analysis 
program for Student’s t test analysis with an assigned significance level of p < 0.01. All 
of the experiments were repeated at least three times. The values are expressed as the 
means ± SEM. 
 
Results 
NFI Gene Expression During Differentiation of MC3T3E1 Cells 
MC3T3-E1cells and C57BL/6 bone marrow stromal cells were changed at 80% 
confluent density (Day 0) to differentiation inducing media (αMEM with FBS, ascorbic 
acid and β-glycerol phosphate) and RNA was isolated on Day 1 – 24.  Relative 
expression levels were determined by qRT-PCR using specific primers described in 
Table 3.  Bar graphs show relative levels of each Nfi gene member mRNA relative to 
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Nfia (Figure 9). Line graphs show change over time relative to the value for each Nfi 
gene on Day 1.  Relative levels were determined by the 2-ΔΔCt method.  Data is based on 
means of 2 qRT-PCR values so statistical testing is not performed. 
To determine if the Nfi gene members were expressed during osteoblast 
differentiation, MC3T3-E1 and mBMSC were grown in differentiation media. Total RNA 
was collected at different time points.  We found that mRNA levels of Nfia and Nfib in 
differentiated MC3T3-T1 cells did not significantly change during deferentiation. In 
contrast, Nfic and Nfix gene expression at later stages of osteoblastogenesis increased 
around 2 fold, compared to Nfia day 1 (Figure 9). Comparable results found in mBMSCs, 
but Nfix expression was remarkably increased (4 fold) compared to Nfia at day 1.  
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Table 3. PCR primers used for assessing mouse Nfi and osteoblast marker gene 
expression.  qRT-PCR was performed with cDNAs synthesized from total RNA 
using random hexamer RT primers.   
.  
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Figure 9. NFI gene expression during differentiation of MC3T3E1 cells. MC3T3-E1cells 
and C57BL/6 bone marrow stromal cells were changed at 80% confluent density (Day 0) 
to differentiation inducing media (αMEM with FBS, ascorbic acid and β-glycerol 
phosphate) and RNA was isolated on Day 1 – 24.  Relative expression levels were 
determined by qRT-PCR using specific primers described in Table 1.  Bar graphs show 
relative levels of Nfi mRNA relative to Nfia. Line graphs show change over time relative 
to the value for each Nfi gene on Day 1.  Relative levels were determined by the 2-ΔΔCt 
method. Data is based on means of 2 qRT-PCR values so statistical testing is not 
performed. 
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Effects of Nfib and Nfix on IGFBP5 Expression in Mouse Osteoblasts 
We examined the effects of Nfi proteins on IGFBP5 promoter activity by 
transiently co-transfecting MC3T3-E1 cells with mouse Nfi expression vectors ( pCH-B 
and pCH-X) and a promoter construct containing bp -252 to +24 of the human IGFBP5 
gene in pGL3.1 luciferase reporter (BP5-p252-luc), which is highly conserved in mouse. 
Nfib was the most active in stimulating IGFBP5 promoter activity at increasing 
concentrations (Figure 10A). In contrast, overexpression of Nfix was not active in 
stimulating IGFBP5 transcription. These results correlate with our previous findings in 
human osteoblasts, which showed that Nfib was the strongest activator of IGFBP5 
transcription among the NFI gene member family.  Knockdown of Nfix in MC3T3-E1 
increased Igfbp5 mRNA levels (Figure 10B). Conversily, transient knockdown of Nfix 
caused a significant decrease in OCN mRNA levels. These results confirm our previous 
findings which demonstrated that Nfix negatively regulates Igfbp5 transcription.  
 
Effects of Nfix and Runx2 Expression on Mouse Osteocalcin 
Promoter Activity in MC3T3-E1 Cells 
Based in our previous results showing that Nfix is the most abundant NFI gene 
member during murine osteoblast differentiation and that it affects osteocalcin mRNA 
levels, we decided to explore its role on the regulation of the OCN promoter.  Given that 
there is a Runx-2 response element on the murine osteocalcin promoter, we decided to 
determine if overexpression of both Nfix and Runx-2 dose dependently activated it. As  
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Figure 10. Effects of Nfib and Nfix on IGFBP5 expression in mouse osteoblasts 
A.Human IGFBP5 promoter luciferase reporter (reference) was cotransfected using 
TurboFectin 8.0 with Nfib or Nfix expression vectors in MC3T3 E1 cells.  B. Short term 
Nfix expression knockdown with siRNA increases IGFBP-5 expression and inhibits 
Osteocalcin expression in MC3T3-E1 osteoblasts.  Cells were transfected by 
electroporation with siRNA oligonucleotides targeting 4 sequences in the mouse Nfix 
mRNA sequence, or with non-targeting control siRNA .  Cells were plated in 6 well 
plates at 50% confluent density and relative expression (Targeting/Non-targeting) was 
determine by qRT-PCR. Similar knockdown of Nfib did not affect IGFBP5 expression 
(data not shown).  * significantly different from control vector. 
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shown in Figure 11, increasing amounts of transiently overexpressed Runx-2 protein dose 
dependently inhibited Nfix-mediated activation of the OCN promoter. These results 
suggest that interactions between Runx-2 and Nfix are perhaps required to modulate 
OCN transcription at earlier stages of osteoblast differentiation. 
 
Long Term Knockdown of Mouse Nfix Expression in MC3T3-E1 
Cells with Lentiviral shRNA Vector 
In order to determine long term effects of Nfix knockdown during osteoblast 
differentiation, we transduced MC3T3-E1 cells with a shRNA lentiviral vector containing 
5 sequences targeting murine Nfix. RNA was collected at different differentiation stages 
and the mRNA expression of several important osteoblast differentiation markers was 
analyzed. Relative mRNA expression of Nfix in Nfix knockdown cells remained 
constantly low through differentiation, compared to the non targeting control (Figure 
12A). Runx-2 expression was decreased in shNFIX targeting cells, compared to the 
control. Its expression remained mostly on plateau, expect at day 24 where it was the 
lowest level (Figure 12B). As expected, one of the osteoblast differentiation markers that 
was greatly affected was OCN (Figure 12C). OCN mRNA levels were dramatically 
decreased in Nfix deficient cells starting at the early time points and dropping its 
expression around -400 fold at later time points  (day 12 and day 24). Another gene that 
was significantly downregulated by Nfix depletion was BSP. Levels of this gene were 
consistently low in all time points (Figure 12D). 
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Figure 11. Effects of NFI-X and Runx2 expression on Mouse Osteocalcin promoter 
activity in MC3T3-E1 cells. Mouse Nfix and human Runx2 expression plasmids were co-
transfected with the p1316-Luc osteocalcin promoter reporter in sub-confluent cultures 
and promoter activity (Luciferase/cell protein) was determined at 48 h.  Promoter 
activation in all groups was greater than control (p < .05). Activation was significantly 
greater with Nfix compared to Runx2 (p < .05).   
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Figure 12. Long term knockdown of mouse Nfix expression in MC3T3-E1 cells with 
lentiviral shRNA vector. RNA was extracted at 1 – 24 days and relative mRNA 
expression was determined by qRT-PCR (N=6), shown as multiples of the Day 1 Non-
targeting group value for each gene (using the 2-ΔΔCt method).  All points for non-
targeting groups are significantly different from Nfix targeting except in the Runx graph, 
where significance is indicated by *.  Significance was determined by T-test on ΔΔCt 
data. 
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Long Term Knockdown of Nfix Expression in MC3T3-E1 Cells with 
Lentiviral shRNA Vector- Effects on Mineralization 
Following the same experimental procedure shown in Figure 12, we made parallel 
cultures that were fixed and stained at 18 and 24 days with Alizarin Red to assess 
mineralization.  There was a large difference in mineralized staining intensity evident 
between non-targeting and Nfix-targeting groups (Figure 13). Quantitation of staining by 
plate reader scanning at 510 nm indicated that mineralization was inhibited by 50% in 
Nfix deficient cells at 18 days and inhibited 70% at 24 days.   These data support the 
conclusion that Nfix is necessary for mouse osteoblast differentiation. 
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Figure 13. Long term knockdown of Nfix expression in MC3T3-E1 cells with lentiviral 
shRNA vector- Effects on mineralization.Cultures transduced as in Figure 12 were fixed 
in methanol at 18 and 24 days, and mineralization was visualized by alizarin red staining.  
Stained wells were scanned at 510 nm using a Biotek Synergy 2 plate reader that 
determines optical density at in 2000 circular spots covering 90% of the 9.4 cm2 well 
surface. NT: non-targeting. Data are mean OD510 ± sem of 3 wells. * significant 
difference between non-targeting and siNfi targeting. 
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Discussion 
In previous studies we demonstrated that the NFI gene family has a significant 
role of in the regulation of the IGFBP5 transcription in human osteoblast cells (Perez-
Casellas et al., 2009). Those studies suggested a possible regulatory role for this TF 
family during the process of osteoblast differentiation. In the present study we 
demonstrated that all four murine Nfi genes are expressed in MC3T3-E1 cells and 
mBMSCs at different stages of osteoblast differentiation. Among these Nfi genes, Nfic 
and Nfix were consistently the most abundant throughout differentiation compared to 
Nfia, which had the lowest relative mRNA expression.  Transient overexpression of 
Murine Nfib increased Igfbp5 promoter activity in MC3T3-E1 pre osteoblast cells.  
However, Nfix modestly increased Igfbp5 promoter activity. These results complemented 
our past studies where we showed similar effects of human NFIX on regulation of Igfbp5 
promoter activity. Results of Nfix expression on promoter activity were corroborated by 
siRNA mediated gene knockdown experiments in which knockdown of endogenous Nfix 
expression increased Igfbp5 mRNA. Relative mRNA expression levels of Ocn were also 
decreased . Based on this finding we decided to determine the role of Nfix and Runx-2 on  
murine Ocn promoter activity. We found that increasing amounts of Runx-2 affected 
Nfix- mediated activation of Ocn transcription. This repressive role of Runx2 when 
coexpressed with Nfix, can be in part a mechanism for regulating Ocn expression during 
early stages of osteoblast differentiation. Long term knockdown of Nfix expression in 
differentiating MC3T3-E1 cells tremendously affected mineral deposition and delayed 
mineralization. We later examined several osteoblast differentiation markers to determine 
if any of them was a target of Nfix. We found that Runx-2, BSP and Ocn mRNA were 
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decreased in Nfix depleted cells. Of these markers, Ocn was the gene that was affected 
the most with up to -400 fold decreas in expression. These results confirmed our previous 
findings that indicated that Nfix positively regulates Ocn transcription. We still need to 
determine if these effects are done directly by Nfix or if there are any other intermediate 
molecules involved in this process.  
In summary, we report novel evidence for Igfbp5 and Ocn transcriptional 
regulation by Nfix proteins in murine cell line MC3T3-E1. Nfix knockdown in 
differentiated MC3T3-E1 cells delayed the mineralization process. Runx-2, Bsp and Ocn 
are  potential genes directly targeted by Nfix during osteoblast differentiation. These 
results suggest Nfix be a significant to regulator of osteoblast differentiation. 
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CHAPTER FOUR 
DISCUSSION 
 
The Insulin-like Growth Factor (IGF) system is a major target of GC inhibition in 
bone. We found that GCs inhibit expression of IGF binding protein-5 (IGFBP5) which 
binds IGFs and stimulates osteoblast activity by IGF dependent and independent 
mechanisms. The work in this dissertation identifies the NFI gene family as an important 
regulator of  IGFBP-5 transcription primarily in human, as well as murine osteoblasts.  
In the first part of this dissertation we we demonstrated that all four Nfi proteins 
can bind to the IGFBP5 proximal promoter region containing a NFI binding site. Murine 
Nfib and Nfix increased IGFBP5 promoter activity in a biphasic manner with Nfib being 
the most active, while Nfia and Nfic mostly decreased promoter activity at increasing 
concentrations. Results of Nfib and Nfic expression on promoter activity were 
corroborated by siRNA mediated gene knockdown experiments in which knockdown of 
endogenous NFIB expression decreased IGFBP5 mRNA and protein levels and decreased 
IGFBP5 promoter activity, while NFIC knockdown increased IGFBP5 expression. We 
found that the NFIC gene was the most highly expressed based on mRNA levels in non-
transformed normal human osteoblasts and osteoblast-like cell lines, except in the MG63 
cell line where NFIB was highly expressed. NFIB1 isoform expression has not been 
reported in human cells, and NFIB3 isoform had very low expression levels in MG63 
cells by qRT-PCR with NFIB3 specific primers (data not shown). NFIC relative 
expression was highest in all three normal human osteoblast cultures, while NFIX and 
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NFIA expression were lowest, which is similar to expression patterns in TE85 and U2OS 
cell lines. While expression levels of NFIA, NFIB and NFIX varied between each of the 
three normal cell preparations, correlation of these differences with osteoblastic 
phenotype, or with tissue donor sex and age was not apparent. Observation that siRNA 
knockdown of NFIB had similar effects on IGFBP5 expression in MG63 cells and 
normal vertebral bone derived cells suggests that the role of NFIB is similar in normal 
osteoblastic cells and cells that have undergone tumor transformation and 
immortalization. 
Comparison of the effects of Nfib and Nfic on IGFBP5 promoter activity, and 
effects of NFIB and NFIC siRNA on expression of IGFBP5, suggest that they could have 
opposing effects on IGFBP5 transcription. The relative abundance of these and the other 
NFI gene products could play a significant role in modulating IGFBP5 expression levels 
in osteoblasts and other cell types. Knockdown of NFIB by siRNA did not increase 
expression of NFIC and NFIX mRNA levels, and knockdown of NFIC or NFIX did not 
alter NFIB expression, suggesting that there may not be compensation of expression 
among the four genes. NFI members bind to the palindromic sequence 
TGGC/A(N)5GCCA or with lower affinity to the half-palindrome. They bind their 
recognition sequence as homo- or heterodimers. Heterodimer formation between NFIB 
and other NFI family members may produce different effects depending on the associated 
NFI proteins. Differential expression, mRNA splicing and heterodimer formation likely 
function to integrate diverse biological signals in modulating NFI effects on expression of 
IGFBP5, other genes and associated cellular functions (Gronostajski et al., 1985). 
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EMSA and ChIP experiments support the conclusions from the functional assays 
of mutant promoter constructs that NFIB transactivates the promoter by binding to the 
NFI consensus binding site in the IGFBP5 proximal promoter region. However, deletion 
of bp -70 to -35 in the BP5-p25270-35-Luc construct did not completely prevent NFI 
activation, suggesting that, in addition to the NFI site at bp -55 to bp -42, sequence 
elements upstream of the NFI site may also be involved in mediating activation of the 
promoter. The present study provides more direct evidence that the NFI site does function 
in transcriptional regulation. Interactions between NFI and AP-2 interact on direct 
regulation of IGFBP5 promoter activity remains to be determined. Competition of AP-2 
and NFI for the overlapping binding site, for example, may be important in modulating 
IGFBP5 gene transactivation, and is being investigating in ongoing studies. 
Recent studies and our current findings indicate that NFI plays important roles 
during bone development and chondrocyte differentiation. Nfix deficient mice displayed 
severe growth retardation and deformation of the spine that was associated with delayed 
endochondral ossification and decreased mineralization (Driller et al., 2007), although the 
growth retardation was reduced in another study by feeding a soft diet (Campbell et al., 
2008). Nfic deficiency in mice inhibited odontoblast differentiation and tooth root 
development (Steele-Perkins et al., 2003). In contrast, Nfia overexpression was reported 
to repress Runx2/Cbfa1 promoter activity in rat osteosarcoma cells by a mechanism 
involving an osteoblast specific enhancer region, while the other NFI family members 
had no effect on activity (Zambotti et al., 2002). 
In the second part of this dissertation we examined a possible regulatory of this 
TF family during the process of osteoblast differentiation. In the present study we 
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demonstrated that all four murine Nfi genes are expressed in MC3T3-E1 cells and 
mBMSCs at different stages of osteoblast differentiation. Among these Nfi genes, Nfic 
and Nfix were consistently the most abundant throughout differentiation compared to 
Nfia, which had the lowest relative mRNA expression.  Transient overexpression of 
Murine Nfib increased Igfbp5  promoter activity in MC3T3-E1 pre osteoblast cells.  
However, Nfix modestly increased Igfbp5 promoter activity. These results complemented 
our past studies. Results of Nfix expression on promoter activity were corroborated by 
siRNA mediated gene knockdown experiments in which knockdown of endogenous Nfix 
expression increased Igfbp5 mRNA. Relative mRNA expression levels of Ocn was also 
decreased . Based on this finding we decided to determine the role of Nfix and Runx-2 on  
murine Ocn promoter. We found that increasing amounts of Runx-2 affected Nfix- 
mediated activation of the Ocn transcription. This repression role of Runx2 when 
coexpressed with Nfix, can be in part a regulatory mechanism of Ocn expression on early 
stages of osteoblast differentiation. Long term knockdown of Nfix in MC3T3-E1 
differentiated cells tremendously affected mineral deposition and had delayed 
mineralization. We later examined several osteoblast differentiation markers to determine 
if any of them was a target of Nfix. We found that Runx-2, BSP and Ocn mRNA were 
decreased in Nfix depleted cells. Of these markers, Ocn was the gene that was affected 
the most with up to -400 fold inhibition of expression. These results confirmed our 
previous findings that indicated that Nfix positively regulates Ocn transcription. We still 
need to determine if these effects are done directly by Nfix or if there are any other 
intermediate molecules involved in this process.  
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In summary, we report novel evidence for Igfbp5 and Ocn transcriptional 
regulation by Nfix proteins in murine cell line MC3T3-E1. Nfix knockdown in 
differentiated MC3T3-E1 cells delayed the mineralization process. Runx-2, Bsp and Ocn 
are  potential genes directly targeted by Nfix during osteoblast differentiation. These 
results suggest Nfix be a significant to regulator of osteoblast differentiation. 
 
Conclusions and Future Directions 
In summary, we report novel evidence for IGFBP5 transcriptional regulation by 
NFI proteins in human osteoblasts. NFIB activates IGFBP5 promoter mainly through 
direct binding to a response element in the proximal promoter, although interaction with 
other cis-acting elements upstream of this sequence may also play a role in NFI 
regulation of IGFBP5 promoter activation. We also demonstrated that murine Nfix 
knockdown affects the osteoblast mineralization, affecting BSP, OCN and Runx-2 
relative mRNA levels. These results suggest that differential regulation of IGFBP5 
expression osteoblast differentiation by NFI gene family transcription factors may be 
significant to modulation of osteoblast proliferation and differentiation. Future studies 
should be performed to determine the possible mechanism of Nfix regulation of murine 
osteoblast differentiation utilizing the MC3T3-E1 cell line model. It would be of great 
importance to investigate if effects of OCN expression by Nfix are direct or through any 
intermediate molecules.  
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